– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion.
By Chris Wack Precigen said Wednesday the U.S. Food and Drug Administration has cleared the Investigational New Drug application to begin a Phase 2 study of its first-in-class PRGN-2009. | May 31, 2023
JPMorgan Chase & Co. started coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a report released on Tuesday morning, The Fly reports. The brokerage issued a neutral rating on the biotechnology company’s stock. PGEN has been the subject of a number of other research reports. HC Wainwright reaffirmed a buy rating and issued […]
JPMorgan Chase & Co. started coverage on shares of Precigen (NASDAQ:PGEN – Get Rating) in a research report sent to investors on Tuesday morning, The Fly reports. The brokerage issued a neutral rating on the biotechnology company’s stock. A number of other equities analysts also recently weighed in on the stock. StockNews.com started coverage on […]